S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
NASDAQ:PLRX

Pliant Therapeutics Stock Competitors

$11.51
+0.03 (+0.26%)
(As of 01/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.90
$11.62
50-Day Range
$10.73
$15.59
52-Week Range
$10.34
$43.92
Volume
143,757 shs
Average Volume
131,682 shs
Market Capitalization
$414.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.04

Pliant Therapeutics (NASDAQ:PLRX) Vs. AGIO, SUPN, SAVA, TVTX, PRTA, MORF, ISEE, DVAX, ZGNX, and BCYC

Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Agios Pharmaceuticals (AGIO), Supernus Pharmaceuticals (SUPN), Cassava Sciences (SAVA), Travere Therapeutics (TVTX), Prothena (PRTA), Morphic (MORF), IVERIC bio (ISEE), Dynavax Technologies (DVAX), Zogenix (ZGNX), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical preparations" industry.

Pliant Therapeutics vs.

Supernus Pharmaceuticals (NASDAQ:SUPN) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk.

99.6% of Supernus Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.3% of Pliant Therapeutics shares are owned by institutional investors. 8.0% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Supernus Pharmaceuticals presently has a consensus price target of $39.50, indicating a potential upside of 28.62%. Pliant Therapeutics has a consensus price target of $46.17, indicating a potential upside of 301.10%. Given Pliant Therapeutics' higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Supernus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Supernus Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Pliant Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Supernus Pharmaceuticals has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.

In the previous week, Supernus Pharmaceuticals had 8 more articles in the media than Pliant Therapeutics. MarketBeat recorded 8 mentions for Supernus Pharmaceuticals and 0 mentions for Pliant Therapeutics. Supernus Pharmaceuticals' average media sentiment score of 0.13 beat Pliant Therapeutics' score of -0.30 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Supernus Pharmaceuticals Neutral
Pliant Therapeutics Neutral

Supernus Pharmaceuticals received 428 more outperform votes than Pliant Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Pliant Therapeutics an outperform vote while only 74.46% of users gave Supernus Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Supernus PharmaceuticalsOutperform Votes
449
74.46%
Underperform Votes
154
25.54%
Pliant TherapeuticsOutperform Votes
21
77.78%
Underperform Votes
6
22.22%

Supernus Pharmaceuticals has higher revenue and earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Supernus Pharmaceuticals$520.40 million3.12$126.95 million$1.5120.34
Pliant Therapeutics$41.82 million9.92-$41.53 million-$2.57-4.48

Supernus Pharmaceuticals has a net margin of 14.49% compared to Pliant Therapeutics' net margin of -914.12%. Supernus Pharmaceuticals' return on equity of 10.56% beat Pliant Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Supernus Pharmaceuticals 14.49% 10.56% 5.33%
Pliant Therapeutics -914.12% -36.28% -34.61%

Summary

Supernus Pharmaceuticals beats Pliant Therapeutics on 13 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Pliant Therapeutics (NASDAQ:PLRX) vs. Its Competitors

TypePliant TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$414.81M$5.74B$4.61B$6.91B
Dividend YieldN/A2.55%2.08%2.84%
P/E Ratio-4.4813.4216.4518.09
Price / Sales9.92464.415,476.99220.05
Price / CashN/A163.8261.1868.55
Price / Book1.448.137.258.51
Net Income-$41.53M$99.84M$99.15M$156.58M
7 Day Performance7.27%-2.44%-3.22%-2.14%
1 Month Performance-16.59%-17.95%-15.26%-12.08%
1 Year Performance-54.11%-33.91%-22.59%-8.36%

Pliant Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGIO
Agios Pharmaceuticals
1.8081 of 5 stars
$30.06
+2.8%
$59.00
+96.3%
-36.2%$1.63B$203.20M1.33562
SUPN
Supernus Pharmaceuticals
2.3948 of 5 stars
$30.71
+5.5%
$39.50
+28.6%
-6.1%$1.62B$520.40M20.34563Analyst Downgrade
Analyst Revision
News Coverage
SAVA
Cassava Sciences
1.7064 of 5 stars
$39.75
+5.3%
$127.75
+221.4%
+90.7%$1.59BN/A-72.2711News Coverage
TVTX
Travere Therapeutics
1.5531 of 5 stars
$25.98
+2.3%
$32.40
+24.7%
+5.2%$1.59B$198.32M-5.70262Analyst Upgrade
Insider Selling
Short Interest ↓
Analyst Revision
PRTA
Prothena
2.6498 of 5 stars
$32.69
+3.8%
$67.50
+106.5%
+160.6%$1.52B$850K31.7466
MORF
Morphic
2.3598 of 5 stars
$40.95
+6.6%
$77.67
+89.7%
+17.9%$1.51B$44.94M-15.3989
ISEE
IVERIC bio
2.3181 of 5 stars
$13.19
+6.4%
$22.00
+66.8%
+143.1%$1.51BN/A-11.8857
DVAX
Dynavax Technologies
2.5881 of 5 stars
$12.60
+6.0%
$23.50
+86.5%
+93.0%$1.51B$46.55M-36.00245
ZGNX
Zogenix
1.8581 of 5 stars
$26.02
+0.3%
$32.10
+23.4%
+30.8%$1.46B$13.64M-5.98218
BCYC
Bicycle Therapeutics
2.2314 of 5 stars
$47.43
+2.3%
$72.88
+53.6%
+80.4%$1.39B$10.39M-16.412,020Short Interest ↓
RXDX
Prometheus Biosciences
2.1448 of 5 stars
$35.46
+7.2%
$42.86
+20.9%
+22.1%$1.38B$1.23M0.0026
TGTX
TG Therapeutics
2.4417 of 5 stars
$9.73
+15.0%
$53.50
+449.8%
-82.2%$1.38B$150K-3.69272Analyst Downgrade
Options Volume
News Coverage
Gap Up
High Trading Volume
VERV
Verve Therapeutics
2.0464 of 5 stars
$28.44
+6.6%
$71.20
+150.4%
N/A$1.37BN/A0.0063Insider Selling
ERAS
Erasca
1.2132 of 5 stars
$11.25
+1.9%
$25.25
+124.4%
N/A$1.36BN/A0.002,021
XENE
Xenon Pharmaceuticals
2.2998 of 5 stars
$26.16
+4.1%
$44.00
+68.2%
+72.3%$1.35B$32.17M-16.05129Options Volume
Analyst Revision
FGEN
FibroGen
1.8131 of 5 stars
$14.50
+3.4%
$29.50
+103.4%
-71.6%$1.34B$176.32M-6.22599
PTGX
Protagonist Therapeutics
2.0265 of 5 stars
$28.15
+6.3%
$59.71
+112.1%
+27.7%$1.34B$28.63M-11.6879
BBIO
BridgeBio Pharma
2.5798 of 5 stars
$9.04
+1.0%
$55.29
+511.6%
-83.9%$1.33B$8.25M-2.31391Analyst Revision
AMRN
Amarin
2.1083 of 5 stars
$3.36
+1.8%
$9.25
+175.3%
-55.0%$1.33B$614.06M84.002,020
AMRX
Amneal Pharmaceuticals
2.5681 of 5 stars
$4.36
+1.6%
$7.88
+80.6%
-11.2%$1.31B$1.99B48.446,000Analyst Upgrade
Short Interest ↓
News Coverage
LYEL
Lyell Immunopharma
1.7848 of 5 stars
$5.25
+2.1%
$24.25
+361.9%
N/A$1.26BN/A0.00189
AMPH
Amphastar Pharmaceuticals
2.2148 of 5 stars
$26.06
+4.0%
$23.67
+9.2%
+32.9%$1.25B$349.85M36.191,980News Coverage
High Trading Volume
ENTA
Enanta Pharmaceuticals
2.4681 of 5 stars
$58.70
+4.5%
$90.25
+53.7%
+14.5%$1.19B$97.07M-15.01141
NGM
NGM Biopharmaceuticals
2.3792 of 5 stars
$15.30
+0.7%
$35.00
+128.8%
-38.4%$1.18B$87.37M-9.50210
MYOV
Myovant Sciences
1.8114 of 5 stars
$12.53
+1.0%
$23.75
+89.5%
-45.8%$1.17B$59.32M-4.80407Earnings Report
Analyst Revision
INVA
Innoviva
1.7165 of 5 stars
$16.03
+1.1%
N/A+29.9%$1.11B$336.79M5.145Upcoming Earnings
News Coverage
PRTC
PureTech Health
1.3665 of 5 stars
$37.50
+0.9%
$71.00
+89.3%
-29.9%$1.08B$11.77M0.0066Short Interest ↓
News Coverage
Gap Up
CDMO
Avid Bioservices
2.4814 of 5 stars
$17.43
+4.6%
$31.67
+81.7%
+19.2%$1.07B$95.87M134.09255
IMGN
ImmunoGen
1.8931 of 5 stars
$5.24
+2.9%
$9.50
+81.3%
-30.3%$1.06B$132.30M-15.4179
PROC
Procaps Group S.A
2.2417 of 5 stars
$9.33
+1.8%
$13.00
+39.3%
N/A$1.05B$106.83M0.00N/A
MOR
MorphoSys
1.2032 of 5 stars
$7.57
+1.7%
$27.08
+257.8%
-75.0%$1.04B$374.30M-5.73615Short Interest ↑
ADCT
ADC Therapeutics
1.9514 of 5 stars
$14.95
+1.9%
$45.20
+202.3%
-54.8%$1.03B$2.34M-4.56208
RCKT
Rocket Pharmaceuticals
2.3531 of 5 stars
$15.77
+3.9%
$65.25
+313.8%
-70.8%$1.02BN/A-5.14101
AXSM
Axsome Therapeutics
2.482 of 5 stars
$26.32
+7.5%
$89.22
+239.0%
-64.8%$992.05MN/A-7.8660Analyst Revision
KROS
Keros Therapeutics
2.1665 of 5 stars
$42.12
+0.5%
$86.67
+105.8%
-30.3%$985.57M$10M-15.5435
MDGL
Madrigal Pharmaceuticals
2.4514 of 5 stars
$56.39
+0.9%
$177.57
+214.9%
-54.2%$964.10MN/A-3.8542Analyst Revision
News Coverage
RANI
Rani Therapeutics
1.3798 of 5 stars
$19.61
+3.2%
$23.50
+19.8%
N/A$960.93MN/A0.002,021Lockup Expiration
Gap Down
MRUS
Merus
1.7298 of 5 stars
$23.58
+1.7%
$40.20
+70.5%
-12.8%$915.19M$29.94M-10.16117
ORGO
Organogenesis
2.7998 of 5 stars
$7.11
+2.8%
$23.00
+223.5%
-32.7%$914.66M$338.30M15.46910Gap Up
RETA
Reata Pharmaceuticals
2.4498 of 5 stars
$24.90
+3.1%
$85.00
+241.4%
-77.5%$906.16M$9.02M-3.22267
RVNC
Revance Therapeutics
2.3781 of 5 stars
$12.55
+1.5%
$23.60
+88.0%
-53.3%$901.03M$15.32M-2.80470
MNKD
MannKind
1.6498 of 5 stars
$3.55
+4.5%
$6.30
+77.5%
-4.6%$891.96M$65.14M-11.09241
DAWN
Day One Biopharmaceuticals
2.0265 of 5 stars
$14.01
+5.4%
$37.33
+166.5%
N/A$867.63MN/A0.0020News Coverage
High Trading Volume
ANAB
AnaptysBio
1.8531 of 5 stars
$31.28
+4.1%
$35.80
+14.5%
+28.7%$864.74M$75M111.7194Analyst Downgrade
KURA
Kura Oncology
1.6331 of 5 stars
$12.88
+1.5%
$40.00
+210.6%
-57.3%$857.24MN/A-6.7189
CRNX
Crinetics Pharmaceuticals
2.1781 of 5 stars
$17.86
+4.0%
$36.80
+106.0%
+18.5%$848.35M$70K-6.4293
CNTA
Centessa Pharmaceuticals
2.1398 of 5 stars
$9.32
+4.5%
$38.00
+307.7%
N/A$837.88MN/A0.002,021Short Interest ↑
HRTX
Heron Therapeutics
1.9248 of 5 stars
$8.15
+0.5%
$26.00
+219.0%
-54.4%$830.77M$88.64M-3.41223
VNDA
Vanda Pharmaceuticals
2.4814 of 5 stars
$14.74
+3.0%
$20.00
+35.7%
-0.6%$821.20M$248.17M24.16292Analyst Upgrade
GHRS
GH Research
1.7464 of 5 stars
$15.81
+1.5%
$26.42
+67.1%
N/A$798.74MN/A0.008
This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.